Amer El Ghali

Amer El Ghali

Auto-generated profile, based on publicly available information

Amer El Ghali

Department of Pharmacy Practice and Administrative Sciences, University of New Mexico College of Pharmacy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2022 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
ACAshlan Kunz Coyne
Ashlan Kunz Coyne
AGAmer El Ghali
Amer El Ghali
DHDana Holger
Dana Holger
NRNicholas Rebold
Nicholas Rebold
MRMichael J. Rybak
Michael J. Rybak
Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa isolates are frequent causes of serious nosocomial infections that may compromise the selection of antimicrobial therapy. The goal of this review is to summarize recent epidemiologic, microbiologic, and clinical data pertinent to the therapeutic management of patients with infections caused by MDR/XDR-P. aeruginosa. Historically, conventional antipseudomonal β-lactam antibiotics have been used for the empiric treatment of MDR/XDR-P. aeruginosa. Owing to the remarkable capacity of P. aeruginosa to confer resistance via multiple mechanisms, these traditional therapies are often rendered ineffective. To increase the likelihood of administering empiric antipseudomonal therapy with in vitro activity, a second agent from a different antibiotic class is often administered concomitantly with a traditional antipseudomonal β-lactam. However, combination therapy may pose an increased risk of antibiotic toxicity and secondary infection, notably, Clostridioides difficile. Multiple novel agents that demonstrate in vitro activity against MDR-P. aeruginosa (e.g., β-lactam/β-lactamase inhibitor combinations and cefiderocol) have been recently granted US Food and Drug Administration (FDA) approval and are promising additions to the antipseudomonal armamentarium. Even so, comparative clinical data pertaining to these novel agents is sparse, and concerns surrounding the scarcity of antibiotics active against refractory MDR/XDR-P. aeruginosa necessitates continued assessment of alternative therapies. This is particularly important in patients with cystic fibrosis (CF) who may be chronically colonized and suffer from recurrent infections and disease exacerbations due in part to limited efficacious antipseudomonal agents. Bacteriophages represent a promising candidate for combatting recurrent and refractory infections with their ability to target specific host bacteria and circumvent traditional mechanisms of antibiotic resistance seen in MDR/XDR-P. aeruginosa. Future goals for the management of these infections include increased comparator clinical data of novel agents to determine in what scenario certain agents may be preferred over others. Until then, appropriate treatment of these infections requires a thorough evaluation of patient- and infection-specific factors to guide empiric and definitive therapeutic decisions.

23 May 2023 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
AEAmer El‐Ghali
Amer El‐Ghali
ACAshlan Kunz Coyne
Ashlan Kunz Coyne
KCKaylee Caniff
Kaylee Caniff
CBCallan Bleick
Callan Bleick
MRMichael J. Rybak
Michael J. Rybak

18 October 2023 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
AGAmer El Ghali
Amer El Ghali
TMTaylor Morrisette
Taylor Morrisette
SASara Alosaimy
Sara Alosaimy
KLKristen Lucas
Kristen Lucas
MTMaria G. Tupayachi-Ortiz
Maria G. Tupayachi-Ortiz
MRMichael J. Rybak
Michael J. Rybak
Infections due to nontuberculous mycobacteria (NTM) continue to increase in prevalence, leading to problematic clinical outcomes. Omadacycline (OMC) is an aminomethylcycline antibiotic with FDA orphan drug and fast-track designations for pulmonary NTM infections, including Mycobacteroides abscessus (MAB). This multicenter retrospective study across 16 U.S. medical institutions from January 2020 to March 2023 examined the long-term clinical success, safety, and tolerability of OMC for NTM infections. The cohort included patients aged ≥18 yr, who were clinically evaluable, and` had been treated with OMC for ≥3 mo without a previous diagnosis of cystic fibrosis. The primary outcome was 3 mo clinical success, with secondary outcomes including clinical improvement and mortality at 6- and 12 mo, persistence or reemergence of infection, adverse effects, and reasons for OMC utilization. Seventy-five patients were included in this analysis. Most patients were female (48/75, 64.0%) or Caucasian (58/75, 77.3%), with a median (IQR) age of 59 yr (49–67). Most had NTM pulmonary disease (33/75, 44.0%), skin and soft tissue disease (19/75, 25.3%), or osteomyelitis (10/75, 13.3%), and Mycobacterium abscessus (60/75, 80%) was the most commonly isolated NTM pathogen. The median (IQR) treatment duration was 6 mo ( 4 – 14 ), and the most commonly co-administered antibiotic was azithromycin (33/70, 47.1%). Three-month clinical success was observed in 80.0% (60/75) of patients, and AEs attributable to OMC occurred in 32.0% (24/75) of patients, leading to drug discontinuation in 9.3% (7/75).

6 February 2024 in Microbiology Spectrum
Verified
Journal Article
Open access
AGAmer El Ghali
Amer El Ghali
ACAshlan Kunz Coyne
Ashlan Kunz Coyne
KLKristen Lucas
Kristen Lucas
MTMolly Tieman
Molly Tieman
XXXhilda Xhemali
Xhilda Xhemali
MRMichael J. Rybak
Michael J. Rybak
Multi-drug resistant gram-negative bacteria present a significant global health threat. Cefiderocol (CFDC), a siderophore cephalosporin, has shown potential in combating this threat, but with the currently available data, its role in therapy remains poorly defined. This multi-center, retrospective cohort study evaluated the real-world application of CFDC across six U.S. medical centers from January 2018 to May 2023. Patients aged ≥18 years and who had received ≥72 hours of CFDC were included. The primary outcome was a composite of clinical success: survival at 30 days, absence of symptomatic microbiologic recurrence at 30 days following CFDC treatment initiation, and resolution of signs and symptoms. Secondary outcomes included time to CFDC therapy and on-treatment non-susceptibility to CFDC. A total of 112 patients were included, with median (interquartile range [IQR]) APACHE II scores of 15 (19–18). Clinical success was observed in 68.8% of patients, with a mortality rate of 16.1% and comparable success rates across patients infected with carbapenem-resistant gram-negative infections. The most common isolated organisms were Pseudomonas aeruginosa (61/112, 54.5%, of which 55/61 were carbapenem-resistant) and carbapenem-resistant Acinetobacter baumannii (32/112, 28.6%). Median (IQR) time to CFDC therapy was 77 (14–141) hours. Two patients experienced a non-anaphylactic rash as an adverse drug reaction. On-treatment non-susceptibility to CFDC was found in six patients, notably due to P. aeruginosa and A. baumannii . IMPORTANCE: CFDC was safe and clinically effective as a monotherapy or in combination in treating a variety of carbapenem-resistant gram-negative infections. Further prospective studies are warranted to confirm these findings.

25 January 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
ACAshlan Kunz Coyne
Ashlan Kunz Coyne
AGAmer El Ghali
Amer El Ghali
KLKristen Lucas
Kristen Lucas
PWPaige Witucki
Paige Witucki
NRNicholas Rebold
Nicholas Rebold
MRMichael J. Rybak
Michael J. Rybak
Limited data suggest that serious infections caused by Enterobacterales with a moderate to high risk of clinically significant AmpC production can be successfully treated with cefepime if the cefepime minimum inhibitory concentration (MIC) is ≤2 µg/mL. However, isolates with a cefepime susceptible dose-dependent (SDD) MIC of 4-8 µg/mL should receive a carbapenem due to target attainment and extended-spectrum β-lactamase (ESBL) concerns. Retrospective cohort study of hospitalized patients with E. cloacae, K. aerogenes or C. freundii bacteremia from January 2015 to March 2022 receiving high dose cefepime or a carbapenem. Cox regression models were used with incorporation of inverse probability of treatment weighting (IPTW) and time-varying covariates. Of the 315 patients included, 169 received cefepime and 146 received a carbapenem (ertapenem n = 90, meropenem n = 56). Cefepime was not associated with an increased risk of 30-day mortality compared to carbapenem therapy (adjusted hazard ratio [aHR] 1.45; 95% confidence interval [CI] 0.79-2.14), which was consistent for patients with cefepime SDD isolates (aHR 1.19; 95% CI 0.52-1.77). Multivariable weighted Cox models identified Pitt Bacteremia score >4 (aHR 1.41; 95% CI 1.04-1.92), deep infection (aHR 2.27; 95% CI 1.21-4.32), and ceftriaxone-resistant AmpC-E (aHR 1.32; 95% CI 1.03-1.59) to be independent predictors associated with increased mortality risk, while receipt of prolonged infusion β-lactam was protective (aHR 0.67; 95% CI 0.40-0.89). Among patients with bacteremia caused by Enterobacterales with moderate to high risk of clinically significant AmpC production, these data demonstrate similar risk of 30-day mortality for high dose cefepime or a carbapenem as definitive β-lactam therapy.

17 August 2023 in Microbiology Spectrum
Verified
Journal Article
Closed access
ACAshlan Kunz Coyne
Ashlan Kunz Coyne
KSKyle Stamper
Kyle Stamper
AGAmer El Ghali
Amer El Ghali
Razieh KebriaeiRazieh Kebriaei
Razieh Kebriaei
BBBiswajit Biswas
Biswajit Biswas
MRMichael J. Rybak
Michael J. Rybak
Our study supports the additional benefit of standard-of-care antibiotics combined with a phage cocktail compared to antibiotic alone against a daptomycin-nonsusceptible (DNS) E. faecium isolate in a high-inoculum simulated endocardial vegetation ex vivo PK/PD model. E. faecium is a leading cause of hospital-acquired infections and is associated with significant morbidity and mortality. Daptomycin is considered the first-line therapy for vancomycin-resistant E. faecium (VRE), but the highest published doses have failed to eradicate some VRE isolates.